产品
编 号：F254724
分子式：C26H44NNaO6S
分子量：521.69
分子式：C26H44NNaO6S
分子量：521.69
产品类型
规格
价格
是否有货
100mg
168
In-stock
500mg
400
In-stock
结构图
CAS No: 207737-97-1
产品详情
生物活性：
Sodium taurodeoxycholate hydrate, a bile acid, is an amphiphilic surfactant molecule synthesized from cholesterol in the liver. Sodium taurodeoxycholate hydrate activates the S1PR2 pathway in addition to the TGR5 pathway.
体内研究：
Taurodeoxycholate (0.5 mg/kg; i.v.; once) confers protection to C57BL/6N mice with sepsis, but does not protect TGR5 KO mice under sepsis.Animal Model:C57BL/6N mice, Lipopolysaccharides (HY-D1056) injection model of sepsis
Dosage:0.5 mg/kg
Administration:Intravenous injection, 30 min or 24 h after LPS injection
Result:Improved the survival rate of mice with sepsis. Decreased liver and kidney damage in septic mice. Ameliorated systemic inflammation and normalized blood pressure in septic mice.
体外研究：
The median plasma concentration of Taurodeoxycholate is 33.9 nM in healthy individuals.Taurodeoxycholate inhibits the binding of N-3H-methylscopolamine to the M3 muscarinic receptor of acetylcholine with an IC50 of 170 μM.Taurodeoxycholate (0.05-1.00 mM; 1-6 days) stimulates intestinal epithelial cell proliferation.Taurodeoxycholate (0.05-1.00 mM; 24 h) induces a significant increase in S-phase concentration and a significant decrease in G1-phase concentration of the cell cycle, increases c-myc protein and mRNA expression in IEC-6 cells.
Sodium taurodeoxycholate hydrate, a bile acid, is an amphiphilic surfactant molecule synthesized from cholesterol in the liver. Sodium taurodeoxycholate hydrate activates the S1PR2 pathway in addition to the TGR5 pathway.
体内研究：
Taurodeoxycholate (0.5 mg/kg; i.v.; once) confers protection to C57BL/6N mice with sepsis, but does not protect TGR5 KO mice under sepsis.Animal Model:C57BL/6N mice, Lipopolysaccharides (HY-D1056) injection model of sepsis
Dosage:0.5 mg/kg
Administration:Intravenous injection, 30 min or 24 h after LPS injection
Result:Improved the survival rate of mice with sepsis. Decreased liver and kidney damage in septic mice. Ameliorated systemic inflammation and normalized blood pressure in septic mice.
体外研究：
The median plasma concentration of Taurodeoxycholate is 33.9 nM in healthy individuals.Taurodeoxycholate inhibits the binding of N-3H-methylscopolamine to the M3 muscarinic receptor of acetylcholine with an IC50 of 170 μM.Taurodeoxycholate (0.05-1.00 mM; 1-6 days) stimulates intestinal epithelial cell proliferation.Taurodeoxycholate (0.05-1.00 mM; 24 h) induces a significant increase in S-phase concentration and a significant decrease in G1-phase concentration of the cell cycle, increases c-myc protein and mRNA expression in IEC-6 cells.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备